TXMD News and Press, TherapeuticsMD Inc. From 04/07/23

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022. “As a result of the transaction with Mayne Pharma Gro...

An agreement between TherapeuticsMD ( NASDAQ: TXMD ) and its interim CFO Michael Donegan has been terminated. Donegan was also serving as chief accounting officer and VP, finance. He is also entitled to separation benefits, including his salary for a year and COBRA benefits for tw...

- Mayne Pharma gains exclusive U.S. commercialization rights for TXMD’s products and acquires certain assets - - TXMD received approximately $153.1 million at closing; portion of proceeds used to repay all outstanding indebtedness under Sixth Street facility and redeem all outstand...

- TXMD to receive approximately $153.1 million in consideration at closing (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up to $30.0 million in additional milestone payments - - Mayne Pharma gai...

Therapeutics MD press release ( NASDAQ: TXMD ): Q3 GAAP EPS of -$3.13 misses by $1.09 . Revenue of $20.92M (-17.7% Y/Y) misses by $9.28M . As of September 30, 2022, the Company’s cash on hand totaled $27.1 million, compared with $65.1 million as of Decem...

- Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year - TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s h...

Summary Today, we put GoodRx Holdings in the spotlight for the first time.  This healthcare concern has destroyed much shareholder value over the past year. However, the company has recently resolved a major dispute and announced a significant restructuring that will reduce i...

TherapeuticsMD ( NASDAQ: TXMD ) has received an additional $7M private investment in the company’s Series A Preferred Stock from Rubric Capital Management. The additional funds will be used for working capital. Under the terms of the company’s financing a...

Maturity Date of Financing Agreement Extended to November 30, 2022 TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that it received an additional $7...

TherapeuticsMD ( NASDAQ: TXMD ) has received a $7M private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction for working capital. Under the terms of the Company...